Founded in 2018, Wugen is developing “off the shelf” cell therapies to treat various cancers. The startup was created via technology licensed from Washington University and is developing so-called natural killer (NK) and T-cell therapies.
Biotech startup, which has raised more than $200M in VC funding, launches clinical trial for cancer drug
View Content